We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Outcome of Idiopathic Macular Hole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00941291
Recruitment Status : Completed
First Posted : July 17, 2009
Last Update Posted : July 17, 2009
Sponsor:
Information provided by:

March 30, 2009
July 17, 2009
July 17, 2009
January 2002
Not Provided
Long-term outcome of idiopathic macular hole surgery [ Time Frame: 37 months ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Outcome of Idiopathic Macular Hole
Long-term Outcome of Idiopathic Macular Hole Surgery
The purpose of this study is to evaluate the role of cataract surgery and cystoid macular edema (CME) on reopening of idiopathic macular holes (IMH).
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
One hundred and thirty patients (135 eyes) with stage 2, 3, or 4 IMH were included after successful IMH repair
Idiopathic Macular Hole
Not Provided
  • vitrectomy in pseudophakic eyes
  • vitrectomy and cataract:combined procedure
  • vitrectomy followed by cataract extraction
  • vitrectomy on phakic eyes
Passemard M, Yakoubi Y, Muselier A, Hubert I, Guillaubey A, Bron AM, Berrod JP, Creuzot-Garcher C. Long-term outcome of idiopathic macular hole surgery. Am J Ophthalmol. 2010 Jan;149(1):120-6. doi: 10.1016/j.ajo.2009.08.003. Epub 2009 Oct 20.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
135
January 2005
Not Provided

Inclusion Criteria:

  • Patients with with stage 2, 3, or 4 Idiopathic Macular Hole after successful Idiopathic Macular Hole repair

Exclusion Criteria:

  • All patients without stage 2, 3, or 4 Idiopathic Macular Hole repair
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00941291
Macular hole 1
No
Not Provided
Not Provided
Professor Creuzot-Garcher Catherine
Centre Hospitalier Universitaire Dijon
Not Provided
Principal Investigator: Catherine Creuzot-Gracher, MD, PhD Ophthalmology unit CHU Dijon
Centre Hospitalier Universitaire Dijon
July 2009